Kintor Pharmaceutical Limited (HKG:9939)
Hong Kong · Delayed Price · Currency is HKD 1.820
-0.070 (-3.70%)
Sep 18, 2026, 4:08 PM HKT
Kintor Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 78.74 | 32.68 | 5 | - | - | 34.23 |
| 78.74 | 32.68 | 5 | - | - | 34.23 | |
Revenue Growth | 616.84% | 553.64% | - | - | - | - |
Cost of Revenue | 44.84 | 24.64 | 3.52 | 1.13 | - | - |
Gross Profit | 33.9 | 8.04 | 1.48 | -1.13 | - | 34.23 |
Selling, General & Admin | 144.21 | 97.88 | 88 | 93.38 | 152.58 | 117.95 |
Research & Development | 64.24 | 85.5 | 71.49 | 849.71 | 827.97 | 767.94 |
Other Operating Expenses | -1.28 | -1.89 | -17.43 | -7.49 | -11.43 | -16.96 |
Operating Expenses | 206.27 | 180.59 | 143.26 | 935.6 | 969.12 | 868.93 |
Operating Income | -172.37 | -172.55 | -141.78 | -936.73 | -969.12 | -834.7 |
Interest Expense | -3.79 | -3.94 | -9.28 | -9.69 | -8.19 | -2.49 |
Interest & Investment Income | 0.11 | 0.11 | 4.21 | 13.08 | 6.88 | 12.05 |
Earnings From Equity Investments | 5.85 | 0.77 | -1.43 | 0.05 | -0.57 | - |
Currency Exchange Gain (Loss) | -0.67 | -0.04 | 3.73 | -3.13 | 16.33 | -17.63 |
EBT Excluding Unusual Items | -170.87 | -175.66 | -144.55 | -936.42 | -954.67 | -842.77 |
Gain (Loss) on Sale of Investments | - | - | 0 | 0.49 | 2 | 0.78 |
Gain (Loss) on Sale of Assets | -0.11 | -0.06 | 2.52 | 0.01 | -0.62 | -0.11 |
Asset Writedown | -27.24 | -27.24 | -13.25 | -132.94 | - | - |
Pretax Income | -198.22 | -202.96 | -155.27 | -1,069 | -953.28 | -842.1 |
Income Tax Expense | -5.6 | -2.85 | 0.02 | -8.04 | 1.09 | - |
Net Income | -192.62 | -200.11 | -155.29 | -1,061 | -954.37 | -842.1 |
Net Income to Common | -192.62 | -200.11 | -155.29 | -1,061 | -954.37 | -842.1 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 479 | 450 | 431 | 429 | 377 | 356 |
Shares Outstanding (Diluted) | 479 | 450 | 431 | 429 | 377 | 356 |
Shares Change | 10.84% | 4.42% | 0.39% | 13.94% | 5.66% | 15.21% |
EPS (Basic) | -0.40 | -0.44 | -0.36 | -2.47 | -2.53 | -2.36 |
EPS (Diluted) | -0.40 | -0.44 | -0.36 | -2.47 | -2.53 | -2.36 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -150.75 | -170.48 | -200.62 | -390.3 | -988.73 | -1,128 |
Free Cash Flow Per Share | -0.31 | -0.38 | -0.47 | -0.91 | -2.63 | -3.16 |
Gross Margin | 43.05% | 24.60% | 29.56% | - | - | 100.00% |
Operating Margin | -218.91% | -527.96% | -2835.64% | - | - | -2438.42% |
Profit Margin | -244.63% | -612.28% | -3105.84% | - | - | -2460.04% |
Free Cash Flow Margin | -191.46% | -521.63% | -4012.36% | - | - | -3294.09% |
EBITDA | -134.52 | -140.87 | -128.63 | -922.88 | -956.45 | -827.97 |
D&A For EBITDA | 37.85 | 31.68 | 13.15 | 13.85 | 12.68 | 6.73 |
EBIT | -172.37 | -172.55 | -141.78 | -936.73 | -969.12 | -834.7 |